Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Sep 21, 2022; 28(35): 5175-5187
Published online Sep 21, 2022. doi: 10.3748/wjg.v28.i35.5175
Table 3 Univariable Cox regression on patient survival to 12 mo
Enduring variablesOverall1, 12-mo survival
Transplant-free, 12-mo survival
HR (95%CI)
HR (95%CI)
Age, per 5-yr1.13 (0.94-1.35)0.95 (0.85-1.07)
Male sex2.05 (0.84-4.99)1.68 (0.94-3.00)
Diabetes0.56 (0.25-1.50)0.39 (0.19-0.81)
Ischaemic heart disease2.00 (0.68-5.92)0.80 (0.29-2.23)
Heart failure0.86 (0.12-6.38)0.35 (0.05-2.55)
Chronic obstructive lung diseaseNE1.02 (0.32-3.30)
Chronic kidney disease1.13 (0.38-3.32)0.82 (0.37-1.83)
Hepatocellular carcinoma2.11 (0.92-4.81)1.55 (0.87-2.76)
Hepatitis B3.36 (1.32-8.53)1.68 (0.75-3.74)
Hepatitis C0.81 (0.32-2.05)1.28 (0.71-2.28)
Alcoholic liver disease0.76 (0.22-2.55)0.94 (0.44-2.01)
Non-alcoholic fatty liver0.51 (0.15-1.73)0.43 (0.18-1.02)
Current smoking5.01 (2.15-11.7)2.27 (1.13-4.56)
Current alcohol intake0.68 (0.42-1.13)0.93 (0.68-1.26)
Time varying variables
MELD score, per 5-points1.28 (0.93-1.77)1.82 (1.41-2.34)
NYHA functional class1.14 (0.74-1.75)1.09 (0.81-1.46)
TIPS procedure0.37 (0.05-2.83)0.13 (0.02-0.96)
Acute kidney injury2.57 (1.13-5.88)2.36 (1.35-4.11)
Thoracocentesis0.51 (0.23-1.16)1.28 (0.70-2.34)
Pneumothorax2.37 (0.80-7.00)2.78 (1.39-5.56)
Intercostal catheter inserted1.56 (0.53-4.62)1.85 (0.90-3.82)
Admission hepatic encephalopathy
None1.00 (reference)1.00 (reference)
Mild0.75 (0.17-3.25)1.21 (0.54-2.70)
Severe11.4 (3.28-39.6)7.93 (2.36-26.6)
Encephalopathy during admission22.30 (0.84-6.32)3.20 (1.65-6.24)
Any encephalopathy2.30 (0.97-5.45)2.21 (1.22-4.03)